 Aethlon Medical, Inc. Nasdaq: AEMD, a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration FDA has approved a supplement to the Companys existing Investigational Device Exemption IDE for the Companys Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2COVID-19 in a new feasibility study. 